This bill matters because it tries to tackle a long-standing challenge in healthcare: how to pay for expensive drugs, especially those with varying or uncertain effectiveness. By officially recognizing and clarifying rules for 'value-based purchasing,' it attempts to shift the financial risk from taxpayers (who fund Medicaid and Medicare) to drug manufacturers if a medicine doesn't work as promised. If this bill becomes law, it could accelerate the adoption of these innovative payment models, potentially leading to more efficient healthcare spending and a greater focus on patient outcomes, rather than just the volume of drugs sold.
Without this bill, value-based purchasing arrangements remain difficult for manufacturers and states to implement due to complex existing drug pricing regulations and potential legal risks under anti-kickback laws. This could stifle innovation in how drugs are paid for, leaving government programs to bear more of the financial risk for costly drugs that may not always deliver their expected benefits.
KEY PROVISIONS
5AI-extracted
PROVISION 01
Allows drug manufacturers to report multiple 'best price' points for a single drug under a value-based purchasing arrangement in Medicaid, as long as the arrangement is offered to all states.
This prevents a discount given to one state based on patient outcomes from forcing manufacturers to offer the deepest discount to all states, which has been a major barrier to VBPs.
PROVISION 02
Excludes certain refunds or rebates given by manufacturers to states under value-based purchasing arrangements (when a patient fails to achieve defined outcomes) from being counted in the calculation of the 'Average Manufacturer Price' (AMP) for Medicaid.
This ensures that these outcome-based refunds don't negatively inflate the discounts manufacturers are required to give to other government programs, making VBPs financially viable.
PROVISION 03
Creates an exception (safe harbor) under the federal Anti-Kickback Statute for payments made by manufacturers to states under a value-based purchasing arrangement when a patient does not achieve expected outcomes.
This removes a significant legal barrier and reduces the risk that manufacturers face when offering outcome-based refunds or rebates.
PROVISION 04
Requires the Department of Health and Human Services to issue guidance to State Medicaid agencies on using value-based purchasing arrangements for inpatient hospital drugs and on how multiple states can enter into joint agreements.
This provides practical instructions and clarity for states looking to implement these complex arrangements, expanding their use beyond traditional outpatient drugs.
PROVISION 05
Excludes certain remuneration received under value-based purchasing arrangements from the calculation of 'Average Sales Price' (ASP) for certain drugs under Medicare Part B, aligning with Medicaid rules.
This provides consistency in how value-based payments are treated across major federal healthcare programs, simplifying compliance for manufacturers.
This bill matters because it tries to tackle a long-standing challenge in healthcare: how to pay for expensive drugs, especially those with varying or uncertain effectiveness. By officially recognizing and clarifying rules for 'value-based purchasing,' it attempts to shift the financial risk from taxpayers (who fund Medicaid and Medicare) to drug manufacturers if a medicine doesn't work as promised. If this bill becomes law, it could accelerate the adoption of these innovative payment models, potentially leading to more efficient healthcare spending and a greater focus on patient outcomes, rather than just the volume of drugs sold.
Without this bill, value-based purchasing arrangements remain difficult for manufacturers and states to implement due to complex existing drug pricing regulations and potential legal risks under anti-kickback laws. This could stifle innovation in how drugs are paid for, leaving government programs to bear more of the financial risk for costly drugs that may not always deliver their expected benefits.
KEY PROVISIONS
AI-extracted
high
Allows drug manufacturers to report multiple 'best price' points for a single drug under a value-based purchasing arrangement in Medicaid, as long as the arrangement is offered to all states.
This prevents a discount given to one state based on patient outcomes from forcing manufacturers to offer the deepest discount to all states, which has been a major barrier to VBPs.
high
Excludes certain refunds or rebates given by manufacturers to states under value-based purchasing arrangements (when a patient fails to achieve defined outcomes) from being counted in the calculation of the 'Average Manufacturer Price' (AMP) for Medicaid.
This ensures that these outcome-based refunds don't negatively inflate the discounts manufacturers are required to give to other government programs, making VBPs financially viable.
high
Creates an exception (safe harbor) under the federal Anti-Kickback Statute for payments made by manufacturers to states under a value-based purchasing arrangement when a patient does not achieve expected outcomes.
This removes a significant legal barrier and reduces the risk that manufacturers face when offering outcome-based refunds or rebates.
med
Requires the Department of Health and Human Services to issue guidance to State Medicaid agencies on using value-based purchasing arrangements for inpatient hospital drugs and on how multiple states can enter into joint agreements.
This provides practical instructions and clarity for states looking to implement these complex arrangements, expanding their use beyond traditional outpatient drugs.
med
Excludes certain remuneration received under value-based purchasing arrangements from the calculation of 'Average Sales Price' (ASP) for certain drugs under Medicare Part B, aligning with Medicaid rules.
This provides consistency in how value-based payments are treated across major federal healthcare programs, simplifying compliance for manufacturers.
The Secretary of Health and Human Services must implement amendments regarding the definition of Average Manufacturer Price through rulemaking.
180 days after the date of enactment
The Secretary of Health and Human Services must issue guidance to State Medicaid agencies on value-based purchasing arrangements for inpatient drugs.
180 days after the date of enactment
The Inspector General of the Department of Health and Human Services must implement the Anti-Kickback Statute exception through rulemaking.
GLOSSARY
AI-written
Value-Based Purchasing Arrangement (VBP)
A payment agreement for a drug where the price paid is adjusted based on how well the drug performs or the health outcomes it achieves for patients. If the drug doesn't work as expected, the manufacturer might provide a refund or discount.
Medicaid 'Best Price'
The lowest price a drug manufacturer sells a covered outpatient drug for to any customer in the United States, after accounting for most discounts. This 'best price' is used to calculate the minimum rebate manufacturers must pay to state Medicaid programs.
Average Manufacturer Price (AMP)
The average price paid to a manufacturer for a covered outpatient drug in the U.S. retail pharmacy market. This is another key figure used to calculate rebates owed by drug manufacturers to Medicaid programs.
Average Sales Price (ASP)
The average price at which a drug is sold in the United States by a manufacturer to all purchasers, after accounting for certain discounts. This price is used by Medicare Part B to determine how much it will pay for certain physician-administered drugs.
Anti-Kickback Statute
A federal law that makes it illegal to knowingly and willfully offer, pay, solicit, or receive any money or item of value to induce or reward referrals for items or services covered by federal healthcare programs like Medicare and Medicaid. It aims to prevent fraud and abuse.
Covered Outpatient Drug
ACTION TIMELINE
2 EVENTS
MAY 7, 25
Introduced in Senate
INTROREFERRAL
MAY 7, 25
Read twice and referred to the Committee on Finance.
